Core Insights - Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases and cancers [3] - The company will participate in two upcoming investor conferences, including a virtual summit and a global healthcare conference in London [1] - Artiva's lead program, AlloNK®, is a non-genetically modified NK cell therapy currently in clinical trials for B-cell driven autoimmune diseases [3] Company Overview - Artiva Biotherapeutics was founded in 2019 as a spin-out from GC Cell, gaining exclusive worldwide rights to NK cell manufacturing technology [3] - The company is headquartered in San Diego, California [4] - Artiva's pipeline includes CAR-NK candidates targeting both solid and hematologic cancers [3] Upcoming Events - Management will participate in TD Cowen's Immunology & Inflammation Summit on November 12, 2025 [1] - The company will also be present at the 2025 Jefferies Global Healthcare Conference in London on November 18, 2025 [1] - Live webcasts of the presentations will be available on Artiva's website, with replays accessible for 90 days [2]
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November